LATEST NEWS
Sep 21, 2021
Infinity BiologiX, Cytox, and Vanguard Pharma announce the US launch of the first, physician use only, polygenic test to predict the risk of cognitive decline due to Alzheimer’s disease
Jul 26, 2021
Cytox strengthens management team to support commercialisation of genoSCORE test to predict risk of cognitive decline due to Alzheimer’s disease
Jul 16, 2021
Cytox appoints BERBĒS as market developer in Spain, to introduce a new test that predicts the risk of cognitive decline due to Alzheimer’s disease
Meet the Team
Dr Richard Pither
CEO
Dr Alex Gibson
Business Development Officer
Dr Paula Daunt
Project and Portfolio Manager
Ian McLellan
Commercial Operations Manager
Dr Qian Gao
Head of Bioinformatics and Genetics
Dr Simon Flint
Clinical Diagnostics Development Lead
Dr Ian Gilham
Chairman
Dr David Whitcombe
Non-executive Director